The
European Medicines Agency
(EMA) opens the door to the emergency use of the antiviral molnupiravir against Covid-19.
This was announced at a press conference by Marco Cavaleri, head of Biological Products and Vaccine Strategy at the EMA.
The European body is reviewing the data of this MSD drug which, according to the data provided by the pharmaceutical company, is capable of halving the risk of death and hospitalization from Covid. While experts reach a conclusion on the drug, the EMA has decided to expedite access to treatment by giving the EU member states a free pass to authorize its use under the
emergency route.
The EMA "is prepared to advise member states so that they
can make this treatment available for emergency use
, before it receives its commercial authorization," said Cavaleri, who explained that the decision to favor emergency use The drug must be interpreted in the context of the new increase in cases that many European countries are experiencing.
The EMA's decision coincides with the authorization of
molnupiravir
by the UK regulatory authorities.
The United Kingdom is, at the moment, the only country that has approved the use of the antiviral.
Molnupiravir is an
antiviral drug
that in a phase 3 clinical study (in 775 patients) conducted by MSD has shown to halve the risk of hospitalization and death in adult patients at risk of developing severe Covid.
According to the criteria of The Trust Project
Know more
See links of interest
The Palm
Georgie Dann dies
Last News
What
Holidays 2021
2022 business calendar
Master Investigation Journalism
Time change
Christmas Lottery 2021
Loteria del Niño 2022
Milan - FC Porto
Real Madrid - Shakhtar Donetsk
Borussia Dortmund - Ajax
Liverpool - Atlético de Madrid
Manchester City - Club Brugge